At yesterday’s Presidential Symposium, favourable results were presented from three phase III trials, which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer. PARP…
Read More
Results from the BAROCCO trial presented yesterday may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer. Continuous cediranib–olaparib shows a trend towards improved progression-free survival (PFS) compared…
Read More
According to Branislav Bystricky, Faculty Hospital TN-Fakultna nemocnica Trencin, Slovakia and Associate Editor of the Daily Reporter practice changing results for women with ovarian cancer will be presented at ESMO 2019 Congress, held in Barcelona,…
Watch Here
